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BACKGROUND: Among older cancer patients, there is
uncertainty about the degree to which venous throm-
boembolism (VTE) and its treatment increase the risk of
death or major hemorrhage.
OBJECTIVE: To determine the prevalence of VTE in a
cohort of older cancer patients, as well as the degree to
which VTE increased the risk of death or major
hemorrhage.
METHODS: We conducted a retrospective cohort study
of linked Surveillance, Epidemiology, and End Results
cancer registry and Medicare administrative claims
data. Patients with any of ten invasive cancers diag-
nosed during 1995 through 1999 were included; the
independent variable was VTE diagnosed concomitantly
with cancer diagnosis. Outcomes included major hem-
orrhage during the first year after cancer diagnosis and
all-cause mortality;
RESULTS: Overall, about 1% of patients who were
diagnosed with cancer also had a VTE diagnosed
concomitantly. After adjusting for sociodemographic
factors and cancer stage and grade, concomitant VTE
was associated with a relative increase in the risk of
death for 8 of the 10 cancer types; the increase in risk
tended to range 20–40% across most cancer types.
Approximately 16.8% (95% confidence interval [CI]
14.9–18.8%) of patients with a concomitant VTE and
7.9% (95% CI 7.7–8.0%) of patients without a VTE
experienced a major hemorrhage during the year after
cancer diagnosis (P value <.001). The excess risk of
hemorrhage associated with VTE varied substantially
across cancer types, ranging from no significant excess
(kidney and uterine cancer) to 11.5% (lymphoma).
CONCLUSION: Concomitant VTE is not only a marker
and potential mediator of increased risk of death among
older cancer patients, but patients with a VTE have a
marked increased risk of major hemorrhage.
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BACKGROUND
Increasing age and cancer are well-established risk factors for
venous thromboembolism (VTE).
1–6 Given that older persons
bear most of the cancer burden, as the population ages the
incidence of cancer-associated VTEs will increase as well.
7,8
However, the epidemiology of VTE in older cancer patients has
not been well described. Prior efforts have largely focused on
either hospitalized patients or were not able to collect longitu-
dinal data on a sufficient number of patients.
1,9,10 As a result,
we lack information about the degree to which VTE increases
the risk of death or anticoagulation-associated complications
such as hemorrhage at the population level.
Prior work has suggested that cancer patients with a VTE
have a two- or threefold greater risk of death.
3,11 If a VTE
diagnosis truly does independently increase the risk of death
threefold, it would have profound implications for prognosti-
cation, management, and prophylaxis of VTE in cancer
patients. It is also possible that the impact of VTE on
mortality may be less pronounced than prior studies have
suggested because VTEs are associated with more aggressive
tumor characteristics and later stage at diagnosis.
10 Prior
studies have not fully accounted for patient and tumor
factors and it is unclear to what degree VTEs are truly a
risk factor for mortality or if they are simply a marker of
more aggressive tumors.
11 Furthermore, given that cancers
vary in the degree to which they are associated with
thrombosis, it could be expected that the impact of VTE on
subsequent survival could vary across cancer types.
12 Infor-
mation about whether VTE is associated with increased risk
of death for different types of cancer could inform decision-
makers about the intensity and duration of VTE prophylaxis
and treatment.
Hemorrhage is a major concern when treating VTE patients
with anticoagulant therapy. Although some work has sug-
gested that patients with a VTE could benefit from prolonged
or even indefinite anticoagulation, the hemorrhage risks for
patients with VTE are uncertain.
13,14 While the frequency of
major hemorrhage reported in clinical trials was quite low,
recent analyses of anticoagulation treatment of both cancer
and noncancer patients in the community setting have
suggested that major bleeding rates were up to tenfold
higher.
4,15,16 Moreover, subgroup analyses suggested that
patients with VTE in the setting of cancer may have a higher
hemorrhage risk than patients with VTE alone.
4,15,16 In
addition, patients with some types of malignancies may be more
prone to major hemorrhage than others because of anatomic
location or disordered hemostasis associated with the underlying
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321malignancy.
17 As a result of these areas of uncertainty, there has
been a call for population-based data documenting the rate of
hemorrhage among cancer patients with VTE.
18
To address these knowledge gaps, we conducted a longitu-
dinal population-based study of older cancer patients to
determine how frequently VTE is diagnosed concomitantly
with cancer and the degree to which VTEs increase the risk
of death or major hemorrhage for different types of cancer.
METHODS
Data Sources and Study Sample
We obtained data on patients diagnosed with cancer during
1995 through 1999 from the linked National Cancer Institute
(NCI) Surveillance, Epidemiology, and End Results (SEER)–
Medicare database. All incident cancer patients who reported
to the SEER registries are cross-matched with a master file of
Medicare enrollment.
19,20 Patient level information available
includes sociodemographic characteristics, cancer type, grade,
site, and stage.
21
We identified all patients who were diagnosed with 1 of 10
common cancer types, selected on the basis of their high overall
incidence rates as well as prior studies demonstrating a relation-
ship with VTE.
11,12 To allow for a 2-year ascertainment period for
previous VTE as well as other comorbid conditions before their
cancer diagnosis (see below), we only included patients who were
67 years of age and older at the time of their cancer diagnosis.
Table 1 demonstrates the construction of the study sample.
Of a total of 410,315 patients in the database, we included only
the 247,785 individuals who were 67 years of age or older at
the time of diagnosis, had a malignant primary lesion diag-
nosed during 1995 through 1999, and had a known cancer
type and month of diagnosis. Exclusions included date of
death before cancer diagnosis (23 patients), ineligible for
Medicare Part A or Part B (17,477), and enrollment in a
managed care plan during a 2-year period before cancer
diagnosis (60,771). These latter groups of patients were
excluded because claims from these beneficiaries were not
included in Medicare claim files. Patients who dropped cover-
age and/or enrolled in a managed care plan after their cancer
diagnosis were censored at the month the fee-for-service
coverage terminated. Finally, we restricted our study sample
to patients who had no diagnosis of VTE (defined as the absence
of any ICD-9 codes) between 6 and 24 months before their
cancer diagnosis to increase the likelihood that patients defined
as having a “concomitant” VTE did not have a prior VTE.
Construction of Variables
A VTE was defined as the diagnosis of either deep venous
thrombosis (DVT) or pulmonary embolism (PE). Cases were
ascertained through hospital admissions associated with spe-
cific International Classification of Diseases, 9th revision, Clin-
ical Modification (ICD-9-CM) codes. The relevant ICD-9-CM
codes used for the diagnosis of DVT or PE were 451.1, 451.11,
451.19, 453.2, 451.81, 453.2, 453.3, 453.8, 453.9, 415.1,
415.11, and 415.19. We included only VTEs for which we could
identify a specific hospital admission. We defined a VTE as
presenting concomitantly with a cancer diagnosis if the VTE
diagnosis was made between 6 months prior and 1 month after
the initial cancer diagnosis. The 6-month prediagnosis window
was selected because many cancer-related VTEs may be diag-
nosed before recognition of the underlying malignancy.
3,22,23
We defined major hemorrhage as an intracranial or gastro-
intestinal hemorrhage requiring hospital admission. The ICD-
9-CM codes for intracranial hemorrhage—codes 430, 431, or
432—were derived from validated work using administrative
claims data.
24 Similarly, ICD-9-CM codes for gastrointestinal
hemorrhage (456.0x, 530.7, 530.82, 531–5, 537.83, 562.02–
03, 562.12–13, 569.3, 569.85, and 578.xx) were also derived
from previously published approaches.
25
Cancer stage was determined using SEER American Joint
Committee on Cancer (AJCC) stage or “historical stage” (coded
as local, regional, or distant) for cancer types in which AJCC
was not available (lymphoma, pancreatic, renal, and prostate
cancers). We used median income according to patient ZIP
code of residence as a proxy for socioeconomic status (SES).
Dichotomous cancer treatment variables were created using
SEER data and Medicare claims to identify patients who had
received cancer-specific surgery, chemotherapy, and radiation
therapy.
26,27
Pertinent “comorbidity” diagnosis codes during the period
before each patient’s cancer diagnosis were obtained from the
inpatient and outpatient claims to identify conditions that
comprise the Charlson comorbidity index.
28 We only included
conditions that appeared on either one inpatient or two
outpatient claims.
28 To enable us to capture additional condi-
tions that could alter the risk of developing a VTE, we also
identified patients with a diagnosis code for atrial fibrillation
(ICD-9 code 427.3) prosthetic heart valve (ICD-9 code 35.20,
35.22, 35.24, 35.26, or 3528), obesity (278.x), hip fracture
(ICD-9 code 352.0, 352.2, 352.4, 352.6, or 352.8), or insertion
of a central venous catheter (CPT code 36533) during the 2-
year period before their cancer diagnosis.
Statistical Analysis
To understand the degree to which the relation between VTE
and mortality is mediated by cancer-related and other factors,
we constructed a series of sequential models for each cancer
type. The initial Cox proportional hazards model incorporated




Total patients 410,315 100.0
Exclusions
Not malignant primary 30,450 7.6
First cancer diagnosis outside
of 1995–1999
40,207 10.0
Age <67 111,142 27.7
Cancer type not of interest 12,241 3.1
Unknown month of cancer diagnosis 2,051 0.5
Eligible 247,785 61.7
Additional exclusions
Date of death before cancer diagnosis 23 0.0
Not eligible for Part A or Part B during
2-year period before cancer
diagnosis
17,477 7.1
HMO enrollment during 2-year
period before cancer diagnosis
60,771 24.5
Prior claim for VTE 3,632 0.9
Study sample 167,385 40.8
VTE=venous thromboembolism.
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between age and mortality), race, and gender as covariates,
with VTE as the independent variable and death as the
outcome. We then added cancer characteristics and therapy
to the model, including stage at diagnosis, histological grade,
chemotherapy, radiation, and cancer-specific surgery. Because
comorbid conditions could affect the probability of receiving
treatment or of developing a VTE, comorbidity was then added
to the model. While SES would not be expected to alter the
physiologic impact of a VTE, we considered lower SES as a
potential mediator of stage and comorbidity. Further, lower
SES could be associated with decreased access to appropriate
anticoagulation care. Hence, a final model was constructed,
which included SES.
We calculated the proportion of patients who had a major
hemorrhage during the first year after cancer diagnosis for
each cancer type according to VTE status. The excess hemor-
rhage risk in VTE patients was estimated by deriving the
absolute difference in hemorrhage rates between the VTE and
non-VTE groups. Rates were compared using two-tailed
Fischer’s exact tests. Finally, we explored the potential role of
hemorrhage in mediating the relationship between VTE and
mortality by adding hemorrhage as a covariate to the final
multivariate model.
RESULTS
The median age of patients in the study sample was 75 years
(interquartile range 71, 81 years). Approximately 48% of
patients were women and 87.4% were white. Overall, about
1% of the patients was diagnosed with a VTE concomitantly
with their cancer diagnosis (Table 2). The cancer types that
were most frequently associated with VTE were ovarian,
kidney, and pancreatic (2.7%, 2.5%, and 2.2%, respectively).
Conversely, breast (0.4%) and prostate (0.4%) cancers were
rarely associated with concomitant VTE. In the bivariate
(unadjusted) analysis, concomitant VTE was strongly associ-
ated with mortality for patients with all types of cancer
(Table 3). The hazard ratio (HR) for the risk of mortality in
patients with a concomitant VTE compared with those without
a VTE ranged from 1.30 (95% confidence interval [CI] 1.18–
1.44) among patients with lung cancer to a high of 3.06 for
patients with cancer of the uterus (95% CI 2.32–4.04).
Mortality. After accounting for demographic factors, cancer
characteristics, and comorbidity, the relation between
concomitant VTE and mortality was attenuated substantially
for patients with cancer of the breast or prostate. For example,
among patients with breast cancer, the unadjusted HR
associated with VTE was 2.30 (95% CI 1.76–3.01). After
adjusting for age and gender, the HR decreased to 1.95 (95%
CI 1.48–2.55) (Table 3). After accounting for cancer charac-
Table 2. Concomitant Venous Thromboembolism (VTE) According
to Cancer Type
Cancer type Number of patients Concomitant VTE
(occurring 6 months




Prostate 40,710 152 0.37
Breast 26,563 102 0.38
Bladder 11,063 79 0.71
Uterus 5,685 71 1.25
Lung 32,348 449 1.39
Colorectal 29,101 453 1.56
Lymphoma 8,022 145 1.81
Pancreas 6,393 139 2.17
Kidney 4,141 103 2.49
Ovary 3,359 92 2.74
Total 167,385 1,785 1.07
Table 3. Concomitant Venous Thromboembolism (VTE) and Risk of Death According to Cancer Type
Cancer
type
Hazard of death associated with VTE (vs no VTE)
Model A: unadjusted Model B: adjusted for
age, sex, race
Model C: adjusted for
factors in Model B +
cancer characteristics
and treatment
Model D: adjusted for
factors in Model C +
comorbidity
Model E: adjusted for













Prostate 2.24 1.78–2.81 1.81 1.44–2.27 1.44 1.14–1.81 1.20 0.95–1.51 1.21 0.96–1.52
Breast 2.30 1.76–3.01 1.95 1.48–2.55 1.11 0.84–1.45 1.01 0.77–1.32 1.01 0.77–1.33
Bladder 2.80 2.17–3.62 2.84 2.20–3.66 1.57 1.21–2.03 1.54 1.19–2.00 1.43 1.13–1.80
Uterus 3.06 2.32–4.04 3.47 2.63–4.59 2.08 1.57–2.75 1.98 1.48–2.64 1.96 1.47–2.62
Lung 1.30 1.18–1.44 1.32 1.20–1.45 1.20 1.09–11.1 1.15 1.04–1.27 1.16 1.05–1.27
Colorectal 1.33 1.18–1.49 1.32 1.17–1.48 1.24 1.10–1.39 1.19 1.06–1.33 1.19 1.06–1.34
Lymphoma 1.95 1.62–2.34 1.82 1.52–2.19 1.78 1.48–2.14 1.62 1.35–1.96 1.63 1.35–1.97
Pancreas 1.31 1.10–1.55 1.35 1.14–1.60 1.28 1.08–1.52 1.26 1.06–1.49 1.26 1.06–1.49
Kidney 1.49 1.19–1.88 1.61 1.28–2.02 1.49 1.18–1.88 1.41 1.12–1.78 1.43 1.13–1.80
Ovary 1.27 1.00–1.61 1.16 0.91–1.47 1.35 1.07–1.72 1.32 1.04–1.68 1.32 1.03–1.68
Each row represents a unique model, as patients with each type of cancer were analyzed separately. Hazard ratio represents the hazard of death for
patients with a concomitant VTE compared to patients with the same cancer type, but without a concomitant VTE. Cancer characteristics include stage at
diagnosis and histologic grade.
CI=confidence interval.
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1.11 and was no longer statistically significant (95% CI 0.84–
1.45). Finally, after accounting for SES and comorbidity, the
HR was 1.01 (95% CI 0.77–1.33). A similar trend was noted
among patients with prostate cancer, in that in the unad-
justed HR associated with VTE was 2.24 (95% CI 1.78–2.81);
the HR decreased sequentially after adjusting for demograph-
ics (HR 1.81, 95% CI 1.44–2.27), cancer characteristics and
treatment (HR 1.44, 95% CI 1.14–1.81), and finally SES and
comorbidity (HR 1.21, 95% CI 0.96–1.52).
Unlike breast and prostate cancers, concomitant VTE was
significantly associated with mortality for patients with the
other eight cancer types, even after adjusting for patient and
cancer factors (Table 3). The HRs associated with VTE ranged
from 1.16 (95% CI 1.05–1.27) for patients with lung cancer to
1.96 (95% CI 1.47–2.62) for patients with cancer of the uterus.
When we added hemorrhage as a covariate to the analysis,
there was little change in the HRs associated with VTE for any
of the cancer types (data not shown).
Hemorrhage. Approximately 16.8% (95% CI 14.9–18.8) of
patients with a concomitant VTE were admitted to the
hospital with a major hemorrhage during the year after their
cancer diagnosis. In contrast, 7.9% (95% CI 7.7–8.0) of patients
without a VTE experienced a hemorrhage-related admission.
The excess risk of hemorrhage in VTE patients was 8.9% (95%
CI 7.0, 10.8; P value for difference <.001). A concomitant VTE
was associated with a significantly higher hemorrhage risk for
patients with 8 of the 10 cancer types studied (Table 4). There
was substantial variation across cancer types with regard to
both baseline hemorrhage risk (i.e., proportion of patients with
no VTE who had a hemorrhage) and the excess hemorrhage
rate associated with VTE.
The excess risk of hemorrhage associated with concomitant
VTE (and the related anticoagulation therapy) was approxi-
mately 6–8% for most cancer types. Among patients with
bladder cancer, for instance, approximately 13.2% of those
who had a concomitant VTE suffered a major hemorrhage, in
comparison to only 5.3% of patients without a concomitant
VTE, yielding an excess hemorrhage rate of 7.9%. The
attributable risk for hemorrhage associated with VTE ranged
from no significant excess (kidney and uterine cancer) hemor-
rhage risk to 11.5% (lymphoma).
DISCUSSION
In a population-based cohort of older patients with cancer, we
found concomitant VTEs were associated with increased risk
of death as well as major hemorrhage for patients with most
types of cancer. The 9% absolute increase in hemorrhage rate
associated with VTE suggests that treatment of VTE is
associated with substantial risk. The risk of death associated
with VTE did not change substantively after adding hemor-
rhage to the multivariate model, suggesting that hemorrhage is
not the mechanism through which VTE increases the risk of
death. This finding should not be misinterpreted as minimiz-
ing the importance of hemorrhage. A major hemorrhage
leading to hospitalization is costly, frightening, and can be
associated with substantial morbidity among patients with a
relatively short life expectancy.
Our analysis builds upon these studies by providing
quantitative, population-based estimates of hemorrhage risk
in the older cancer population. In one analysis of 181 cancer
patients with VTE, the 12-month cumulative incidence of
major bleeding was 12.4% (95% CI 6.5–18.2).
4 Of note, the
same analysis also investigated the hemorrhage rate in VTE
patients without cancer and found that it was only 4.9% (95%
CI 2.5–7.4).
4 Similarly, a review of more than 2,000 patients
with VTE, with and without cancer, demonstrated a bleeding-
related hospitalization rate of 11.4 to 14.9 per 100 patient-
years, and that patients with cancer had a higher hemorrhage
risk.
15 These hemorrhage rates are substantially higher than
the rate (1.1 events/100 person-years) reported in a recent
meta-analysis of anticoagulation trials, which included
patients with and without cancer, across a spectrum of age
groups.
16 This discrepancy between trial and community
outcomes is likely because of differences in study populations,
monitoring of therapy, and the fact that many of the trials have
included patients with and without cancer.
16,29
Table 4. Concomitant Venous Thromboembolism (VTE) and Major Hemorrhage During the First Year After Cancer Diagnosis According
to Cancer Type
Cancer type Concomitant VTE No concomitant VTE Excess hemorrhage rate
in VTE patients (%)
P value*
N % hemorrhage N % hemorrhage
Prostate 129 8.5 38,371 3.6 4.9 0.007
Breast 80 10.0 24,822 3.1 6.9 0.0035
Bladder 68 13.2 10,327 5.3 7.9 0.001
Uterus 54 1.9 5,248 4.4 −2.5 0.36
Lung 382 12.6 26,897 8.1 4.5 0.003
Colorectal 388 25.8 25,836 17.9 7.9 <0.001
Lymphoma 131 22.1 6,936 10.6 11.5 <0.001
Pancreas 115 24.3 4,836 16.4 7.9 0.020
Kidney 95 10.5 3,612 8.4 2.1 0.45
Ovary 82 14.6 2,773 8.0 6.6 0.033
Total 1,524 16.8 149,658 7.9 8.9 <0.001
Concomitant VTE: VTE diagnosed between 6 months before and 1 month after cancer diagnosis. Major Hemorrhage defined as intracranial or
gastrointestinal bleeding requiring hospitalization.
*P value with two-sided Fisher’s exact test for difference in hemorrhage rate between patients with VTE versus without VTE for each cancer type.
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the Outpatient Bleeding Risk Index, which includes risk
factors such as age greater than 65 years, prior gastrointesti-
nal hemorrhage, and specific comorbid conditions including
atrial fibrillation stroke, anemia, prior myocardial infarction,
or renal insufficiency.
18,30 In the context of prior work showing
that cancer increases the risk of hemorrhage, and our finding
that hemorrhage risk can vary substantially across cancer
types, future work should seek to identify bleeding prediction
tools for validation in cancer patients.
Our findings suggest that prior estimates of the relation
between VTE and mortality may have been inaccurate because
of confounding by tumor characteristics.
1 In one case control
study of cancer patients that accounted for age, gender, and
cancer type, patients with a VTE had a HR for mortality of 2.20
(95% CI 2.05–2.45).
3 Although patients with a VTE were
significantly more likely to have metastatic disease than
patients without a VTE, cancer stage was not accounted for
in this analysis. In contrast, we found that the impact of VTE
on mortality was attenuated after accounting for these factors
in patients with breast or prostate cancer. This suggests that a
substantial portion of the increased mortality risk previously
attributed to VTE for patients with these cancer types may
actually be attributed to underlying tumor characteristics and
stage at presentation. Because they are common malignancies
and are frequently diagnosed at an early stage, inadequate
adjustment for cancer type and stage can lead to biased
assessments of VTE outcomes.
There are several considerations to note in the interpreta-
tion of this study. Although other authors have used ICD-9
codes to identify patients with diagnosed VTE, and some
s t u d i e sh a v er e p o r t e dt h a tt h i si sar e l a t i v e l ya c c u r a t e
approach, many cases of VTE may not be clinically recognized,
and some clinically recognized cases may not be appropriately
coded.
1,23,31–33 We focused on VTEs that were diagnosed with
an associated hospital admission to increase the likelihood
that the VTEs were acute. However, because it is unclear
whether administrative data can reliably capture the clinical
diagnosis of VTE, future work should use alternate data
sources to assess outcomes associated with VTE. Similarly,
other comorbid conditions may not be reliably captured using
administrative claims.
While there has been a trend toward increased treatment of
VTEs in the outpatient setting, low molecular weight heparin
was not approved for outpatient VTE treatment until Decem-
ber 31, 1998—near the end of our study period.
34 Our study
included only older persons, so it is unclear whether our
findings would generalize to a younger cancer patient popula-
tion. Finally, because pharmacologic and laboratory data were
not available, we were unable to identify anticoagulation
management patterns for patients with VTE. Further work
should identify the degree to which the substantial hemorrhage
rate noted in our sample is attributable to appropriateness of
therapeutic monitoring, or the interaction of anticoagulation
risks with specific cancer characteristics or other comorbid
illnesses. Finally, we repeated the analysis after excluding
patients who were diagnosed in 1999, as low molecular weight
heparin was available during this time and outpatient treatment
would have affected the analysis. We found no substantive
change in the adjustedhazard of death associatedwithVTE after
excluding patients diagnosed in 1999.
Our findings shed new light on the scope and impact of VTE
on older cancer patients. The substantial risk of hospitaliza-
tion with a major hemorrhage in the first year after diagnosis of
a VTE emphasizes the importance of identifying opportunities
for risk reduction in this population. We also found that
although VTE is associated with increased risk of death, this
risk varied across cancer types and was, in many cases,
attenuated by adjusting for underlying tumor characteristics.
With the number of newly diagnosed cancer patients and
cancer survivors increasing dramatically, it is imperative to
further clarify the optimal approach to older cancer patients
who are at risk for VTE and those who have already experi-
enced a VTE.
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